10-K: Whitehawk Therapeutics Shifts Focus to ADC Therapies After FYARRO Divestiture

Whitehawk Therapeutics divests its FYARRO business to focus on developing a portfolio of antibody-drug conjugates (ADCs) targeting various cancers.

Summary

• Whitehawk Therapeutics, formerly Aadi Bioscience, has divested its FYARRO business to KAKEN for $102.4 million, closing the transaction on March 25, 2025.
• The company is now focused on developing three next-generation ADCs (HWK-007, HWK-016, and HWK-206) through a license agreement with WuXi Biologics, targeting PTK7, MUC16, and SEZ6, respectively.
• The company anticipates submitting IND applications for HWK-007 in the second half of 2025, HWK-016 by the end of 2025, and HWK-206 in mid-2026.
• The company believes its existing cash, cash equivalents and short-term investments will enable it to conduct its planned operations into 2028.
• The company plans to utilize an outsourced model for research, development and manufacturing operations.

Sentiment

Score: 7

Explanation: The document presents a strategic shift for the company, focusing on a promising area of cancer therapeutics (ADCs). While it acknowledges past losses and the risks inherent in drug development, the company expresses confidence in its technology, team, and future prospects. The divestiture of FYARRO provides capital for the new strategy.

Positives

• The company has a clear strategy focused on next-generation ADC architecture.
• The company is targeting clinically validated targets with opportunities for differentiation.
• The company is utilizing an efficient virtual model with outsourced clinical development and manufacturing.
• The company has a strong investor base and experienced management team.

Negatives

• The company has incurred significant net losses since its inception and expects to continue to incur significant net losses for the foreseeable future.
• The company is a preclinical-stage biopharmaceutical company with a limited operating history.
• The company's success depends on its ability to obtain regulatory approval for its product candidates, which is not guaranteed.
• The company faces significant competition in the oncology market.

Risks

• The company may be unable to obtain regulatory approval for its product candidates.
• The company may face delays or difficulties in enrolling patients in clinical trials.
• The company may face significant competition from other companies developing cancer therapies.
• The company's success depends on its ability to attract and retain key personnel.
• The company's stock price is volatile.

Future Outlook

The company anticipates submitting IND applications for its ADC Therapies between the second half of 2025 and mid-2026 and believes its existing cash, cash equivalents and short-term investments will enable it to conduct its planned operations into 2028.

Management Comments

• The company is applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments.
• The company is well positioned to execute its strategy to develop and commercialize the ADC Therapies and future pipeline assets.

Industry Context

The ADC market is expected to grow to over $50 billion by 2030, with next-generation ADCs showing improved efficacy and safety profiles compared to first-generation ADCs.

Comparison to Industry Standards

• The company's approach to ADC development, utilizing the CPT113 linker-payload technology, aims to improve upon the limitations of first-generation ADCs, such as those using MMAE-based payloads.
• The company's lead product candidate, HWK-007, is positioned to be among the first next-wave ADCs with a TOPO1 inhibitor payload to enter the clinic, potentially offering superior outcomes compared to existing PTK7-targeting ADCs like cofetuzumab pelidotin.
• The company's MUC16-targeting ADC, HWK-016, is designed to bind to the membrane-bound portion of MUC16, potentially overcoming the antigen sink issue associated with circulating CA125, a limitation of previous MUC16-targeting therapies like DMUC4064A.
• The company's SEZ6-targeting ADC, HWK-206, utilizes a biparatopic antibody approach, which preclinical models suggest can improve binding and internalization compared to monotopic antibodies like the one used in ABBV-706, an ADC developed by AbbVie.

Management Changes

Legal Proceedings

• The company was involved in an arbitration with EOC Pharma (Hong Kong) Limited, which concluded with a favorable outcome for the company.

Stakeholder Impact

• Shareholders: The company's strategic shift and financial outlook may impact shareholder value.
• Employees: The company's restructuring and workforce reductions have impacted employees.
• Patients: The company's focus on ADC Therapies aims to provide improved treatment options for cancer patients.

Next Steps

• Complete IND-enabling studies for HWK-007, HWK-016, and HWK-206.
• Submit IND applications to the FDA for HWK-007 in the second half of 2025, HWK-016 by the end of 2025, and HWK-206 in mid-2026.
• Initiate Phase 1 clinical trials for the ADC Therapies.
• Continue to build the portfolio through strategic partnerships.

Key Dates

Keywords

Antibody-drug conjugates, ADC Therapies, FYARRO, Oncology, Clinical trials, Pharmaceuticals, Biotechnology, WuXi Biologics, PTK7, MUC16, SEZ6